1. Home
  2. |Experience
  3. |Corporate and Transactional
  4. |Emerging Companies and Venture Capital

Emerging Companies and Venture Capital

Overview

Today’s startups require more than vision—they needed a proven growth strategy. One that’s powered by a diverse team of trusted advisors who are immersed in the ecosystem of emerging companies and venture capital. Envisioning a practice designed to support the rapid growth and agility of emerging companies, we created GrowthStudio™. GrowthStudio powered by Crowell, offers a dedicated team of lawyers, who have collectively represented hundreds of emerging companies, venture funds, and corporate investors, throughout all investment cycles. Our roots hail from leading technology companies to leading legal services firms. We supplement our deep experience with a shared enthusiasm that comes with launching a new venture.

Entrepreneurs and early stage companies rely on sound legal and business guidance from experienced practitioners as they navigate a wide range of issues. Whether it’s the early, middle, or late stages of business growth, GrowthStudio is a one-stop-shop that collaborates with you at every stage. We meet your complex legal challenges with customized and sensible solutions, legal tools and resources, to successfully navigate through formation, capital raising, regulatory compliance, team hiring, and the evolving stages of commercialization.

Our areas of focus include:

  • Emerging Companies
  • Entrepreneur and Executive Advisory
  • Capital Needs and Financing Transactions
  • Early Stage Investors
  • Venture Capital
  • Venture Debt
  • Growth-Stage General Corporate Counseling
  • Commercial Transactions
  • Secondary Sales/Liquidity Rounds
  • Mergers & Acquisitions
  • Initial Public Offerings
  • Public Company Advisory

To learn more about our Emerging Companies and Venture Capital practice, please visit growthstudio.crowell.com.

Contacts

See All Professionals

Insights

Client Alert | 4 min read | 01.07.26

FDA Request for Information Signals New Path for VC Firms and their Portfolio Companies in Federal Contracting

On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.[i]The RFI includes 19 questions, with responses due by 2:00 p.m. ET on January 18, 2026....

View All Insights

Insights

Client Alert | 4 min read | 01.07.26

FDA Request for Information Signals New Path for VC Firms and their Portfolio Companies in Federal Contracting

Firm News | 1 min read | 12.02.25

Crowell & Moring Represents Antares in $96 Million Series B

Firm News | 1 min read | 11.05.25

Crowell & Moring Represents Farcast in $5 Million Strategic Investment and Expanded Commercial Partnership With Telesat

Firm News | 1 min read | 10.24.25

Crowell Represents Möbius Industries in $3.8 Million Pre-Seed Funding Round

View All Insights

Professionals

View All Professionals

Insights

Client Alert | 4 min read | 01.07.26

FDA Request for Information Signals New Path for VC Firms and their Portfolio Companies in Federal Contracting

On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.[i]The RFI includes 19 questions, with responses due by 2:00 p.m. ET on January 18, 2026....

View All Insights